Home > Estrogen/progestogen Receptor & > Toremifene Citrate

Toremifene Citrate

柠檬酸托瑞米芬,NSC 613680,NK 622,FC 1157a,NK-622,NK622,NSC613680,NSC-613680

Toremifene Citrate 是第二代选择性雌激素受体调节剂，对雌激素受体的IC50为1μM。

目录号
EY0492
EY0492
EY0492
EY0492
纯度
99.45%
99.45%
99.45%
99.45%
规格
25 mg
50 mg
100 mg
500 mg
原价
150
190
280
600
售价
150
190
280
600
库存
现货
现货
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Toremifene Citrate is an oral selective estrogen receptor modulator (SERM), used in the treatment of advanced breast cancer.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Kangas, L., et al., A new triphenylethylene compound, Fc-1157a. I. Hormonal effects. Steroid Biochem. 36, 191-195, (1990)
    [2] Gauri J Sabnis, Luciana Macedo, Olga Goloubeva, Toremifene - Atamestane; Alone or In Combination: Predictions from the Preclinical Intratumoral Aromatase Model. J Steroid Biochem Mol Biol. 2008 January; 108(1-2): 1-7.
    [3] Matthew R Smith, Selective Estrogen Receptor Modulators to Prevent Treatment-Related Osteoporosis.Rev Urol. 2005; 7(Suppl 3): S30-S35.

    分子式
    C32H36ClNO8    		 分子量
    598.08    		 CAS号
    89778-27-8    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    >10 mg/mL    		 Water
    <1 mg/mL    		 Ethanol
    <1 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT01417754 Circulatory; Change Drug: Toremifene Satakunta Central Hospital|Tampere University Hospital|University of Tampere Phase 3 2010-09-01 2011-08-22
    NCT01214291 Risk of Bone Fracture Occurrences Drug: Toremifene GTx|Ipsen Phase 3 2011-03-01 2013-11-13
    NCT02344940 Breast Cancer Drug: Toremifene|Drug: Tamoxifen Shanghai Jiao Tong University School of Medicine Phase 4 2014-12-01 2016-10-22
    NCT02506790 Breast Cancer Drug: metformin|Drug: Melatonin|Drug: Toremifene Petrov Research Institute of Oncology Phase 2 2015-07-01 2015-07-27
    NCT00129142 Prostate Cancer|Osteoporosis|Fractures Drug: Toremifene Citrate GTx Phase 3 2003-10-01 2013-11-13
    NCT00534846 Breast Pain Drug: toremifene|Drug: placebo Satakunta Central Hospital|University of Tampere Phase 3 2007-04-01 2009-05-12
    NCT02353429 Desmoid Type-fibromatosis Drug: Toremifene Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|Associazione Italiana per la Ricerca sul Cancro Phase 2 2012-11-01 2015-01-30
    NCT00106691 Preneoplastic Conditions|Prostatic Intraepithelial Neoplasia Drug: Toremifene 20 mg|Drug: Placebo GTx Phase 3 2005-01-01 2013-01-31
    NCT00437359 Breast Neoplasms Drug: Toremifene citrate|Drug: Anastrozole Japan Breast Cancer Research Network Phase 2 2007-05-01 2012-03-28
    NCT00003865 Ovarian Cancer Drug: toremifene George Washington University|National Cancer Institute (NCI) Phase 2 1999-07-01 2008-07-23
    NCT00267553 Breast Neoplasms|Neoplasms, Hormone-Dependent Drug: Atamestane|Drug: toremifene|Drug: letrozole Intarcia Therapeutics Phase 3 2005-11-01 2007-09-07
    NCT00020735 Prostate Cancer Drug: toremifene|Procedure: conventional surgery|Procedure: neoadjuvant therapy Joel Nelson, MD|National Cancer Institute (NCI)|University of Pittsburgh Phase 2 2001-04-01 2015-12-01
    NCT02132390 Breast Cancer|Chemotherapy Induced Amenorrhea|Ovarian Function Suppression Drug: Goserelin|Drug: Toremifene Peking Union Medical College Hospital Phase 3 2014-05-01 2014-06-02
    NCT00002595 Desmoid Tumor Drug: toremifene|Procedure: conventional surgery Lutheran General Hospital|National Cancer Institute (NCI) Phase 2 1991-07-01 2013-07-09
    NCT02132000 Breast Cancer Patients in Premenopausal|Estrogen and/or Progesterone Receptor Positive Drug: toremifene or tamoxifen Fengxi Su|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Phase 2|Phase 3 2014-04-01 2014-05-03
    NCT00010322 Breast Cancer Drug: atamestane|Drug: toremifene Intarcia Therapeutics Phase 3 2000-10-01 2014-03-24
    NCT01072318 Breast Cancer Drug: Letrozole Korean Breast Cancer Study Group Phase 4 2010-01-01 2010-02-18
    NCT00097344 Breast Neoplasms|Neoplasms, Hormone-Dependent Drug: Atamestane|Drug: Toremifene|Drug: Letrozole|Drug: Aromatase inhibition|Drug: Estrogen receptor blocker|Procedure: Hormone therapy|Procedure: Endocrine therapy|Procedure: Antiestrogen therapy Intarcia Therapeutics Phase 3 2004-12-01 2007-08-21
    NCT02089854 Female Breast Cancer Drug: Toremifene; Anastrozole Peking Union Medical College Hospital Phase 4 2014-11-01 2016-11-30
    NCT00044291 Breast Neoplasms|Neoplasms, Hormone-dependent Drug: atamestane|Drug: toremifene|Drug: letrozole|Drug: aromatase inhibition|Procedure: hormone therapy|Procedure: endocrine therapy|Procedure: antiestrogen therapy Intarcia Therapeutics Phase 3 2002-06-01 2015-07-29
    NCT02271282 Normal Healthy Volunteers Drug: Toremifene|Drug: Placebo|Drug: GHRH/Ghrelin combined Injection Mayo Clinic Phase 1 2014-12-01 2016-09-12
    NCT02097459 Breast Cancer Drug: Anastrozole|Drug: Tamoxifen|Drug: Toremifene Peking Union Medical College Hospital Phase 3 2014-03-01 2016-05-24
    NCT01352091 Breast Cancer Drug: Zoladex+AI|Drug: TAM Fudan University Phase 3 2008-05-01 2011-05-10
    NCT00028353 Prostatic Intraepithelial Neoplasia Drug: GTX-006 (Acapodene) GTx Phase 2 2001-04-01 2013-11-13
    NCT00002529 Breast Cancer Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: epirubicin hydrochloride|Drug: tamoxifen citrate|Drug: toremifene International Breast Cancer Study Group Phase 3 1993-05-01 2013-04-03
    NCT02025309 Neuromuscular Monitoring|Sugammadex Effect Device: Neuromuscular monitorisation Ankara University Phase 4 2013-07-01 2013-12-30
    NCT02788201 Urothelial Carcinoma|Bladder Cancer|Urinary Bladder Neoplasms Drug: 75 approved agents|Other: COXEN National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Phase 2 2016-05-20 2017-01-24

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：